Intec Pharma Ltd reports results for the quarter ended in March - Earnings Summary

Indaptus Therapeutics

17/05/2021 14:36

* Intec Pharma Ltd  NTEC.OQ  reported a quarterly adjusted loss
of 96 cents​​ per share for the quarter ended in March. The mean
expectation of two analysts for the quarter was for a loss of 87
cents per share.
* Reported revenue was zero​;  analysts expected zero. 
* Intec Pharma Ltd's reported EPS for the quarter was a loss
of 96 cents​.
* The mean earnings estimate of analysts had risen by
about 12.6% in the last three months.​ 
* In the last 30 days there have been no earnings estimate
revisions by analysts covering the company. 
* Intec Pharma Ltd shares had fallen by 21.3% this quarter and
lost 0.3% so far this year.
* The company reported a quarterly loss of $4.23 million.
* Wall Street's median 12-month price target for Intec Pharma
Ltd is $13.00 
* The current average analyst rating on the shares is "buy" and
the breakdown of recommendations is 1 "strong buy" or "buy," 2
"hold" and no "sell" or "strong sell." 
This summary was machine generated May 17 at 01:36 p.m. GMT.
​All figures in US dollars